In Vivo Activity of HSR-903, a New Fluoroquinolone, against Respiratory Pathogens
AUTOR(ES)
Yoshizumi, Satoshi
FONTE
American Society for Microbiology
RESUMO
The in vivo activity of HSR-903, a new fluoroquinolone, against major bacteria which cause respiratory tract infections was evaluated. HSR-903 was active against experimental respiratory tract infections in mice challenged with penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae and Haemophilus influenzae strains. Treatment with HSR-903 reduced the bacterial numbers in infected murine lungs. In accord with the pulmonary clearance results, the rates of survival for mice treated with HSR-903, sparfloxacin, levofloxacin, ciprofloxacin, and benzylpenicillin were 50, 30, 10, 0, and 0%, respectively, 14 days after being infected with penicillin-resistant S. pneumoniae. A pharmacokinetic study with pneumonic mice showed that the levels of HSR-903 in the lungs were seven to eight times higher than those in the plasma. These results indicate that clinical studies of HSR-903 against respiratory tract infections may be warranted.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=105542Documentos Relacionados
- Effect of HSR-903, a New Fluoroquinolone, on the Concentration of Theophylline in Serum
- In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic.
- In Vitro Activity of HSR-903, a New Oral Quinolone, against Bacteria Causing Respiratory Infections
- In vitro activity of HSR-903, a new quinolone.
- In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone, against pathogens of veterinary importance.
